

ENZO BIOCHEM INC  
Form 8-K  
June 07, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 7, 2016**

**Enzo Biochem, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**New York**

(State or Other Jurisdiction of Incorporation)

**001-09974**                      **13-2866202**  
(Commission File Number) (IRS Employer Identification No.)

**527 Madison Avenue**



**Item 8.01 Other events**

On June 7, 2016 Enzo Biochem, Inc. (the “Company”) issued a press release titled “Enzo Biochem Announces New York State Approval of New Women’s Test Based on Proprietary Technology” for its AmpProbe Candidiasis™ assay.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

99.1 Press Release of Enzo Biochem, Inc., dated June 7, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: June 7, 2016 By: /s/ Barry W. Weiner  
Barry W. Weiner  
President